PET/MRI evaluation of hepatobiliary tumors.

Abstract

Positron-emission tomography magnetic resonance imaging (PET/MRI) has emerged as a powerful hybrid molecular imaging technique in clinical practice, overcoming initial technical challenges to provide comprehensive anatomic and metabolic information. This advanced modality combines the superior soft tissue contrast of MRI with the metabolic insights of PET, offering advantages in hepatobiliary imaging, including improved detection of small liver metastases and reduced radiation exposure. The evolution of PET/MRI technology has been marked by significant advancements, such as the development of MRI-compatible PET detectors and sophisticated motion compensation techniques. These innovations have enhanced image quality and co-registration accuracy, crucial for hepatobiliary imaging. The integration of time-of-flight capability and silicon photomultipliers has further improved spatial resolution and sensitivity. PET/MRI protocols for liver imaging typically involve a whole-body scan followed by a targeted liver examination, utilizing radiotracers like FDG and DOTATATE. This approach allows for comprehensive staging and detailed liver assessment in a single session, potentially altering management decisions in up to 30% of patients with intrahepatic cholangiocarcinoma. While PET/MRI excels in characterizing various hepatobiliary lesions, including hepatocellular carcinoma and cholangiocarcinoma, challenges remain in differentiating certain benign entities like small hemangiomas from metastases. Ongoing research and clinical experience continue to refine the role of PET/MRI in hepatobiliary imaging, promising improved diagnostic accuracy and patient care.